BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T223210
CREATED:20230405T225751Z
LAST-MODIFIED:20230405T225751Z
UID:37019-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:ADC Toxicity Summit
DESCRIPTION:There is a vast number of ADCs that never make it to the clinic let alone to market\, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity\, their translatability into the clinic\, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. \nThe inaugural ADC Toxicity Summit is coming to Boston\, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action\, discuss shared challenges associated with translating in vivo toxicity data to the clinic\, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market. \nTake a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit. \nUniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists\, through to nonclinical\, translational\, and clinical experts\, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients. \n3 reasons why you can’t miss out on joining include: \n\nSelect optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie\nHear how companies with commercially approved ADCs mitigated toxicities in the clinic\, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute\nUncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb\, Iksuda and Merck & Co\n\nHarnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies\, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release\, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.
URL:https://www.pharmajournalist.com/event/adc-toxicity-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T223210
CREATED:20230516T104255Z
LAST-MODIFIED:20230516T104255Z
UID:37192-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:2nd Annual Targeted Radiopharmaceuticals Summit
DESCRIPTION:With the exciting news that Novartis has received US FDA approval for Pluvicto for previously-treated patients with PSMA-positive metastatic castration-resistant prostate cancer\, the TRP space is continuing to go from strength to strength. \nThis is why the upcoming 2nd Annual Targeted Radiopharmaceuticals Summit US program is even more comprehensive than ever\, bringing you a tracked agenda covering the whole TRP landscape from discovery\, translation\, to clinical\, late stage progress and challenges – a unique opportunity for your entire team to learn and network. \nJoin us to: \n\nExplore the novel target selection to re-route targeted radiopharmaceuticals from a niche-label therapeutic\nNavigate the regulation and reimbursement challenges to improve the accessibility of targeted radiopharmaceuticals\nReview theragnostic in the clinic to exploit the two-birds-one-stone potential of TRPs\nDiscover the potential combination therapies with DDRi’s and IO to unlock synergy with other modalities\nHarness the platform technologies for optimized preclinical evaluation of drugs\n\nAll presented by top industry players such as Clarity Pharmaceuticals\, SOFIE Biosciences\, Lantheus\, Fusion Pharmaceuticals\, Rayze Bio\, Telix Pharmaceuticals\, OranoMed\, Actinium Pharmaceuticals\, and many more. \nDownload the brand-new event guide here to see a full overview 3-day content and speaker faculty: https://ter.li/8hn0z2
URL:https://www.pharmajournalist.com/event/2nd-annual-targeted-radiopharmaceuticals-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T223210
CREATED:20230601T114828Z
LAST-MODIFIED:20230601T114828Z
UID:37256-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:Fusion Protein Engineering & Developability Summit
DESCRIPTION:Design & Engineer Functional & Manufacturable Novel Fusion Proteins \nPrepare to be captivated by the Fusion Protein Engineering & Developability Summit\, the ultimate event tailored to drug developers with groundbreaking fusion protein pipelines. This conference is an absolute game-changer that should be at the top of your priority list! \nAs the demand for practical and effective engineering techniques to expedite the development of viable drugs into clinical applications skyrockets\, this highly anticipated summit offers an unrivalled opportunity. Join forces with esteemed experts from industry giants like Roche\, Merck\, Bristol Myers Squibb\, Abbvie\, and an array of other distinguished names. Seize this unique occasion to connect with fellow drug developers\, exchange innovative ideas and strategies\, and gain invaluable insights into cutting-edge fusion applications. \nPrepare for a whirlwind of activity across the action-packed three-day agenda\, including: \n\nCutting-Edge Insights: Gain exclusive access to the latest breakthroughs in fusion protein engineering\, encompassing the most recent research and emerging trends in this dynamic field.\nPractical Learning: Immerse yourself in hands-on workshops led by industry experts\, designed to enhance your skills and knowledge in must-know areas.\nReal-World Case Studies: Immerse yourself in over 17+ data-driven case studies presented by renowned drug developers\, offering profound insights and best practices.\nEngaging Discussions: Engage in lively panel discussions and roundtable sessions\, fostering debates and knowledge exchange on hot topics such as novel linker selection and the identification of PK/PD rules.\nNetworking Opportunities: Forge valuable connections with 60+ protein engineers\, therapeutic developers\, and influential industry leaders during 7+ hours of dedicated networking\, including the renowned speed networking session.\n\nWith a stellar lineup of 25+ speakers\, 3 immersive hands-on workshops\, and 2 days packed with data-driven case studies\, this event is set to become the unequivocal highlight of the year and you cannot afford to miss it! \nTo know more visit: https://ter.li/uuyrdu
URL:https://www.pharmajournalist.com/event/fusion-protein-engineering-developability-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T223210
CREATED:20230608T113503Z
LAST-MODIFIED:20230608T113503Z
UID:37317-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:4th Gamma Delta T Therapies Summit
DESCRIPTION:Established industry leaders and emerging innovators such as Adicet Bio\, IN8Bio\, Sanofi\, Merck\, LAVA Therapeutics\, Takeda and Leucid Bio are driving the race to demonstrate the potential of Gamma Delta T Therapies as cytotoxic\, off-the-shelf solid tumor therapies\, spurred by early indications of clinical efficacy. \nThe 4th Gamma Delta T Therapies Summit returns to Boston this July as the ultimate Industry-focused forum to advance your Gamma Delta T research\, spanning dedicated 2 tracks of content to maximize your Clinical & Product Optimization and Research & Translational Development. Join 150+ expert industry peers for 2 full days of sessions and a pre-conference workshop and deep-dive day\, building on early clinical successes\, highlighting process and engineering innovations and leveraging early clinical insights to cast the spotlight onto Gamma Delta T Therapies in the clinic. \nTo know more visit: https://ter.li/69o2yc
URL:https://www.pharmajournalist.com/event/4th-gamma-delta-t-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230726
DTEND;VALUE=DATE:20230729
DTSTAMP:20260515T223210
CREATED:20230310T085409Z
LAST-MODIFIED:20230310T085611Z
UID:36783-1690329600-1690588799@www.pharmajournalist.com
SUMMARY:3rd mRNA-Based Therapeutics Summit
DESCRIPTION:The 3rd mRNA-Based Therapeutics Summit returns to Boston this July\, cementing its position as the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines. \nDownload the event program here. \nThis year’s meeting promises 75+ deep-dive case studies from a speaker faculty that is 85% new for this year’s agenda\, featuring presentations from the FDA\, Pfizer\, Moderna\, BioNTech\, Sanofi and many more. \n \nExpect 100+ world-class speakers from large pharma\, innovative biotechs\, and key opinion leaders of academia\, 5 dedicated tracks and 3 days of immersive content on discovery\, translation\, clinical development\, chemistry\, manufacturing and controls (CMC) and logistics to overcome industry hurdles of optimized dosing\, targeted delivery\, safety and scalability to achieve regulatory success in infectious and rare diseases\, cancer and beyond! \nRegister your team here to join 500+ mRNA experts in July.
URL:https://www.pharmajournalist.com/event/3rd-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230822
DTEND;VALUE=DATE:20230825
DTSTAMP:20260515T223210
CREATED:20230406T130638Z
LAST-MODIFIED:20230406T130725Z
UID:37042-1692662400-1692921599@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation 2023
DESCRIPTION:Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field\, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index. \nThe inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs\, with low aggregation and controlled release\, which can be replicated at scale. \nSee the complete event guide here. \nHere’s a snapshot of our speaker faculty\, including expert industry leaders such as: \n\nSayumi Yamazoe\, Senior Principal Scientist\, Bristol Myers Squibb\nRomas Kudirka\, Director\, Chemistry & Bioconjugation\, Bolt Biotherapeutics\nDonglu Zhang\, Senior Fellow\, Genentech\nPaul Song\, Chief Scientific Officer\, Genequantum\nPatrick Higgs\, Principal Scientist\, Chemistry\, Iksuda\nNoah Bindman\, Principal Scientist\, Seagen\nMarc-André Kasper\, Director\, Chemistry & Early Discovery\, Tubulis\nPaul Sauter\, Director\, Chemistry\, VERAXA\n\n…and many more!\nFind the full list of speakers and session details here. \nBe part of the first industry-dedicated meeting for professionals just like you\, interested in learning about developments in the field of ADC linkers and conjugations\, and overcoming common challenges with stability.
URL:https://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-2023/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230823
DTEND;VALUE=DATE:20230825
DTSTAMP:20260515T223210
CREATED:20230608T112726Z
LAST-MODIFIED:20230608T112726Z
UID:37312-1692748800-1692921599@www.pharmajournalist.com
SUMMARY:RNA Assay Development & Screening Summit
DESCRIPTION:Bringing together technical experts from biopharma and academia\, the brand-new RNA Assay Development & Screening Summit has been curated to support in-house assay development and screening strategies to find new RNA targets\, and ultimately determine biological effect in a manner that supports progression from early discovery to drug candidate. \nDeveloped in collaboration with experts in the field\, join 60+ key opinion leaders from the likes of Arrakis Therapeutics\, Expansion Therapeutics and NextRNA at the first technical RNA meeting of its kind! \nCome away with actionable insights after deep diving into the latest technical expertise and explore learnings from data-driven case studies. \nDon’t miss this unique opportunity expand and validate your assay and screening strategies and accelerate the path to the clinic! Learn more – https://ter.li/8fsu01
URL:https://www.pharmajournalist.com/event/rna-assay-development-screening-summit/
LOCATION:The Bostonian Boston\, 26 NORTH STREET\, BOSTON\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230902
DTSTAMP:20260515T223210
CREATED:20230503T044916Z
LAST-MODIFIED:20230503T044916Z
UID:37116-1693267200-1693612799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit
DESCRIPTION:Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE. \nThis decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.   \nThe 8th CAR-TCR Summit is returning to Boston as the industry’s trusted\, definitive\, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.   \nAcross 3 conference days with 8 content tracks\, and an additional 6 deep-dive workshops\, bootcamp\, focus day\, diversity session\, C-level think tank and more\, 200+ CAR and TCR experts will lead you and over 1\,000 peers in discussions that will accelerate your pipeline\, bringing better drugs to patients faster. \nTo know more visit: https://ter.li/ztgick
URL:https://www.pharmajournalist.com/event/8th-car-tcr-summit/
LOCATION:Hynes Convention Center\, 900 Boylston St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260515T223210
CREATED:20230516T102107Z
LAST-MODIFIED:20230517T113503Z
UID:37184-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:2nd Oligonucleotides CMC & Analytical Development Summit 2023
DESCRIPTION:Rapid development and rising demand of oligonucleotide drugs is fuelling revolutionary steps in biopharma investment and technology advancement for pipeline progression. The prospect of defining impurities and suitable CQAs for long-term scalable manufacturing looks to propel oligonucleotide development to patients at a much faster rate. \nThe 2nd Oligonucleotides CMC & Analytical Development Summit returns this August to Boston. 70+ industry leaders will unite at this unique forum dedicated to CMC and Analytical Experts. \nAcross 3 days\, senior leaders will leverage knowledge and share thought leadership focused on improving analytical characterization\, effectively preparing CMC data for IND filing and scaling up with long-term manufacturing in mind. \nBuilt with experts from AstraZeneca\, Alexion Pharmaceuticals\, Biogen \, revolutionize your drug development protocols by keeping your finger on the pulse at this hotly anticipated summit. \n\nExplore analytical control strategies for therapeutic oligonucleotides to ensure safety and quality with regulatory compliance\nOvercome the challenges of capacity when out-sourcing to propel and expedite oligonucleotide development\nGet interactive in roundtable discussions\, picking the brains of your peers and expert speakers on how biopharma is currently navigating the regulatory landscape\nFacilitate cost-efficient large-scale production of oligonucleotides now we are moving into larger patient populations and non-rare disease indications\nTurbocharge novel and complex oligonucleotide development in an in-depth workshop outlining CMC\, Analytical Characterization and Impurity Control of conjugates\n\nDownload your Full Event Guide Here for more details on what you can expect at the 2nd Oligonucleotides CMC & Analytical Development Summit. Including the expert speaker faculty\, a full in-depth agenda and the incredible networking and collaboration opportunities on offer this year.
URL:https://www.pharmajournalist.com/event/2nd-oligonucleotides-cmc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230829
DTEND;VALUE=DATE:20230901
DTSTAMP:20260515T223210
CREATED:20230516T103454Z
LAST-MODIFIED:20230516T103454Z
UID:37187-1693267200-1693526399@www.pharmajournalist.com
SUMMARY:3rd Inner Ear Disorders Therapeutics Summit
DESCRIPTION:The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum\, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss. \nHowever\, in a space that has also had to battle with multiple clinical failures\, there’s a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval. \nThat’s why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer\, bringing together the community to collectively accelerate development of drug-based approaches\, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets. \nThis meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear. \nWhat to expect from the 2023 meeting: \n\nExplore how to improve clinical trial design to increase the number of clinical trials achieving regulatory approval\nDelve into the numerous delivery methods being employed in industry and explore how to optimize delivery to the inner ear\nEvaluate the current opportunities and limitations of using animal models to accurately predict preclinical efficacy and translational success\nLeverage valuable insights from VC investors to understand the key considerations made when investing in or forging partnerships with biotechs focussing on inner ear disorder therapeutics\nNavigate the complex landscape of improving the diagnostics of inner ear disorders by developing a robust diagnostic toolbox and strategizing how to supplement patient-reported outcome measures\n\nView the full agenda here: https://ter.li/a2ivra
URL:https://www.pharmajournalist.com/event/3rd-inner-ear-disorders-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230908
DTSTAMP:20260515T223210
CREATED:20230515T131825Z
LAST-MODIFIED:20230515T131825Z
UID:37179-1693872000-1694131199@www.pharmajournalist.com
SUMMARY:5th Exosomes Based Therapeutic Development Summit
DESCRIPTION:The 5th Exosome Based Therapeutic Development Summit returns with a refreshed program\, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications. \nThis year features a brand-new focus day on analytical development\, diving into characterization assays\, purification\, and potency assays to enable robust translation into the clinic. \nThis is the most comprehensive\, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes\, achieve GMP manufacturing of EVs for clinical applications\, and successfully deliver payloads to the target tissue by evaluating route of administration to accelerate candidates towards commercialization. \nThe 2023 conference covers: \n\nEmerging standardized analytical strategies for optimized characterization\, purification\, and isolation to improve batch consistency and reproducibility towards successful scale-up\nKey pre-clinical and clinical updates across a range of therapeutic areas\nThe latest advancements of targeted delivery and therapeutic payloads\nThe challenges of large-scale manufacturing\nNavigating the complex regulatory landscape across the drug development timeline\n\nView the full agenda here: https://ter.li/q4fnpd
URL:https://www.pharmajournalist.com/event/5th-exosomes-based-therapeutic-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230908
DTSTAMP:20260515T223210
CREATED:20230519T095236Z
LAST-MODIFIED:20230519T095236Z
UID:37210-1693872000-1694131199@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Immunogenicity Summit 2023
DESCRIPTION:The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers\, along with leading academics\, regulators\, and key service providers\, all making strides with improving risk assessments\, monitoring\, and mitigating against AAV gene therapy immunogenicity. \nRegistering for 2023 will grant you access to keynote plenaries from leading gene therapy figures\, deep-dive discussions into pressing preclinical and clinical developments\, and highly appraised networking opportunities with 150+ of your peers\, all to leave you with the actionable tools\, insights\, and connections you need to enhance your immunogenicity-focused work. \nTo know more visit: https://ter.li/vk8xwq
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-immunogenicity-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230905
DTEND;VALUE=DATE:20230909
DTSTAMP:20260515T223210
CREATED:20230606T104920Z
LAST-MODIFIED:20230606T104920Z
UID:37280-1693872000-1694217599@www.pharmajournalist.com
SUMMARY:13th World Clinical Biomarkers & CDx Boston 2023
DESCRIPTION:The hotly anticipated 13th World Clinical Biomarkers & CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization\, reimbursement and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster. \nWhether you are working in Oncology\, NASH\, or Neuroscience\, join 600+ Directors\, Heads and VPs of Clinical Biomarkers\, Translational Medicine\, Precision Medicine & Companion Diagnostics together with drug and diagnostic developers\, regulatory experts\, payors and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes. \nTo know more visit: https://ter.li/849j6q
URL:https://www.pharmajournalist.com/event/13th-world-clinical-biomarkers-cdx-boston-2023/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230911
DTEND;VALUE=DATE:20230914
DTSTAMP:20260515T223210
CREATED:20230704T143300Z
LAST-MODIFIED:20230704T143518Z
UID:37419-1694390400-1694649599@www.pharmajournalist.com
SUMMARY:7th Complement-Based Drug Development Summit
DESCRIPTION:With the recent FDA approval of SYFOVRE and more decisions and approvals expected in 2023\, the Complement-Based Drug Development Summit is returning for its 7th year in a timely fashion. Be the first to view this year’s Event Guide below! \n7th Complement-Based Drug Development Summit\nSeptember 11-13\, 2023\nView Agenda \nReuniting experts across Nephrology\, Neurology\, Ophthalmology\, and Haematology\, join the leading companies showcasing the latest preclinical and clinical progress for complement-based therapeutics. \n\nWith 30+ expert speakers from: AGTC\, Alexion\, Alnylam\, Amgen\, Annexon\, Apellis – and that’s just the A’s!\nCovering more complement targets than ever before including C5aR2\, Factor Bb and Combination Therapy\, alongside an increased coverage of diseases\nFull of content for your whole team covering the most pressing challenges – from evaluating the value proposition of different fragments to target to designing clinical trials with high-risk patient populations\n\n \n​​​​View the full list of sessions and expert speakers here. \n​​​​​​This world-class speaker faculty will evaluate the entirety of the complement landscape\, from scientific understanding to strategic\, commercial intelligence. This means that no matter your role in the field\, you’ll leave with tangible insights to further develop your complement pipeline.
URL:https://www.pharmajournalist.com/event/7th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T223210
CREATED:20230714T121304Z
LAST-MODIFIED:20230714T121304Z
UID:37455-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:LNP Characterization & Analytical Development Summit
DESCRIPTION:Fingerprinting Your LNP Drug Product Quality\, Safety\, Efficacy & Regulatory Compliance \nWith the recent breakthroughs from Verve Therapeutics\, Vertex-Arbor Bio\, and Mana.bio propelling the field of LNP technology forward at lightning speed beyond mRNA vaccines\, the LNP Characterization & Analytical Development Summit is your must-attend meeting to deep dive into the latest technologies and approaches throughout product lifecycle and strengthen your lipid nanoparticle characterization\, bioanalytical and assay development competencies. \nWith unmissable case studies from the likes of Pfizer\, Moderna\, AstraZeneca\, Ultranegyx\, Merck and SINTEF\, this is the definitive forum to benchmark and learn with the LNP community who unite for the first time. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nAnalyze LNP structure and morphology to relay into functional data and analytical practices with Ultragenyx and Pfizer\nOptimize the characterization of payloads to foresee the outcome of the LNP complex with Hopewell Therapeutics\, Beam Therapeutics and Moderna\nDevelop assays which align with mechanisms of action and portray total functionality of the LNP with NIST\, Editas Medicine and AstraZeneca\n\nDon’t miss this opportunity to supercharge your analytics\, and together with 60+ characterization and analytical scientists\, get inspiration to derive best practice\, and support next generation of therapeutics to patients with safety and efficacy. \nTo know more visit: https://ter.li/z7dmih
URL:https://www.pharmajournalist.com/event/lnp-characterization-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230912
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T223210
CREATED:20230720T121753Z
LAST-MODIFIED:20230720T121753Z
UID:37490-1694476800-1694735999@www.pharmajournalist.com
SUMMARY:3rd Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:Your one-stop shop to capturing industry’s most exciting developments to tackle rare & genetic kidney diseases. From evaluating real-world outcomes to uncovering underlying pathophysiology to interrogating translational models\, the 3rd Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to give industry the opportunity to unite towards a shared goal and share strategic insights to move from bench to bedside and bring efficacious therapies to patients faster. \nTo know more visit: https://ter.li/jy2ot0
URL:https://www.pharmajournalist.com/event/3rd-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230915
DTSTAMP:20260515T223210
CREATED:20230810T114925Z
LAST-MODIFIED:20230810T114925Z
UID:37605-1694563200-1694735999@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:Wearable Injectors and Connected Devices USA  \nConference: September\, 13 – 14 2023  \nBoston\, USA  \nWebsite: http://www.wearableinjectors-usa.com/PharmaJournalist-EL \nAdvancing digital health and on-body drug delivery devices for enhanced patient experience  \nFollowing the success of the Wearable Injectors and Connected Devices Europe conference\, SAE Media Group will be bringing the conference to Boston to cater to Big Pharma\, Biotech and Device Developers in the USA. \nAs the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. The conference will delve into on-body device design and development\, latest advances in connectivity and digital integration of wearable devices\, and opportunities for enhancement of user-interface through human factors case studies. The conference will also address challenges in regulations surrounding wearable injectors and connected devices with case studies and an FDA keynote on cybersecurity. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in September 2023! \nKey Reasons to Attend: \n\nDiscover the latest advances in wearable injector design and development as well as emerging technologies for improved drug delivery\nUnderstand and gain insight into the regulations surrounding electronic devices and wearable injectors such as labelling requirements and clinical study expectations\nDelve into the digital integration of medical devices for improved user experience and strategies to ensure connected ecosystems are safe with an FDA Cybersecurity update\nBenchmark against connected injector case studies and gain insight into key considerations during development such as battery selection\nEngage in the latest strategies for implementing user centricity into device design to meet patient needs and increase adherence\n\nWHO SHOULD ATTEND? \nDevice Developers \nCombination Product Developers \nSmart Packaging Developers and Designers \nSmart Device Developers \nDrug- Delivery Developers \nConnected/Digital Health Developers
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230922
DTSTAMP:20260515T223210
CREATED:20230726T074357Z
LAST-MODIFIED:20230726T074357Z
UID:37521-1695081600-1695340799@www.pharmajournalist.com
SUMMARY:7th IPF Summit
DESCRIPTION:FIbroGen’s recent Phase 3 trial failure for pamrevlumab exemplifies the critical time point the pulmonary fibrosis field is currently at as drug developers move through in-human to Phase 2 to Phase 3 trials to get the next disease-modifying drug to the patients in need. \nThe 7th IPF Summit (September 19-21 | Boston) returns at this crucial stage for the drug development and academic communities to come together to address R&D bottlenecks\, troubleshoot key discovery challenges\, and share exclusive data to accelerate the latest ideas and innovations in the IPF field and supercharge a new era of IPF therapeutics. \nIf you haven’t yet seen the line-up of 42+ expert speakers\, take a look at the full program in the event guide! \nAre you looking to address and solve challenges with IPF therapeutic development\, such as:   \n\nUnderstanding cell cross-talk in the lung pathobiology of IPF\, including epithelial and endothelial cells\nHarnessing precision medicine for IPF including patient selectivity\, combinational therapies\, and biomarkers\nWhether to incorporate imaging into your preclinical and clinical development and the potential of using imaging as an endpoint in IPF?\n\nThen this is the event for you! This is your unique opportunity to leverage knowledge from world-leading IPF industry experts and KOL academics on the latest developments to overcome\, discovery\, preclinical\, translational\, and clinical\, challenges of IPF therapeutic development for successful advancement of therapeutic candidates to in-human studies and beyond. \nJoin experts from the likes of Boehringer Ingelheim\, Genentech\, Pfizer\, AstraZeneca\, BMS\, Pliant\, Galecto\, Vicore\, Avalyn\, Pieris\, Moderna\, Takeda and more who have already saved their places at the meeting. \nSee pricing and registration options here!
URL:https://www.pharmajournalist.com/event/7th-ipf-summit/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230926
DTEND;VALUE=DATE:20230929
DTSTAMP:20260515T223210
CREATED:20230704T142733Z
LAST-MODIFIED:20230704T142733Z
UID:37413-1695686400-1695945599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit
DESCRIPTION:Returning to Boston as the world’s only industry-leading meeting focused on mRNA process development and manufacturing\, join 200+ VPs\, Directors and Heads of Process Development\, MSAT\, Technical Operations\, CMC and more from large pharma\, innovative biotechs\, and academia. \nDownload the program here: https://ter.li/5o4hdl \nThis must-attend meeting will provide you with technical insight and know-how from the largest process development and manufacturing speaker faculty to date\, enabling you to revolutionize your processes for effective industrialization. \nSpanning three tracks dedicated to Research Scale\, IND-Enabling & Clinical Scale\, and Commercial Scale\, this year’s meeting will dive deep into the challenges\, requirements\, innovations and opportunities to improve your design\, development and scale-up solutions from drug substance to drug product for regulatory and market readiness. \nRegister here: https://ter.li/nu15iq
URL:https://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit/
LOCATION:Boston Convention and Exhibition Center (BCEC)\, 415 Summer Street\, Boston\, MA\, MA 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231002
DTEND;VALUE=DATE:20231005
DTSTAMP:20260515T223210
CREATED:20230608T110740Z
LAST-MODIFIED:20230608T110740Z
UID:37302-1696204800-1696463999@www.pharmajournalist.com
SUMMARY:5th TIL Therapies Summit
DESCRIPTION:With the first commercial TIL therapy brewing at Iovance\, along with various clinical readouts which are set to come to fruition in 2023\, the race is on for the next generation of modified TIL to enter the clinic. \n \nReturning as the only forum to address bottlenecks in end-to-end TIL development\, the 5th TIL Therapies Summit is designed exclusively for TIL experts to fast-track your program into the clinic and beyond. \nUnite with this niche community across industry and academia as pioneers from Iovance Biotherapeutics\, Turnstone Biologics\, Achilles Therapeutics and Lyell Immunopharma share clinical updates\, next-gen engineering\, and novel innovations to turbocharge preclinical and clinical development of safe\, scalable and effective TIL therapies. \nWith 23+ expert speakers\, 8 new companies and a brand-new Manufacturing & Characterization Bootcamp\, you won’t want to miss this unrivalled opportunity to connect and collaborate with industry leaders. \nDon’t let your team get left behind! Join us as we accelerate the next wave of TIL therapies into the clinic and beyond. Find out more – https://ter.li/mk23q3.
URL:https://www.pharmajournalist.com/event/5th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231009
DTEND;VALUE=DATE:20231011
DTSTAMP:20260515T223210
CREATED:20230810T115308Z
LAST-MODIFIED:20230810T115430Z
UID:37608-1696809600-1696982399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference & Expo
DESCRIPTION:Wearable Injectors and Connected Devices Conference & Expo \n9 – 10 October 2023 | London\, UK \nhttp://www.wearable-injectors.co.uk/PharmaJournalist-EL \nStrategies to advance digital health and on-body drug devices for large volume delivery \nSAE Media Group are proud to announce the 4th annual Wearable Injectors and Connected Devices conference. As the need for at home self-administration and routes for delivery of time-dependent and high-volume drug delivery grows\, on-body injectors and connected devices hold great opportunity. \nThe conference will delve into on-body device design and development\, enhancing digital connectivity for injectable devices\, strategic approaches to wearable device design\, regulatory considerations and primary container considerations for large volume delivery systems. \nAs part of SAE Media Group’s leading Injectable series of conferences\, we bring together high-level experts from big pharma and device developers to network and share knowledge to advance R&D. The two-day conference will not only bring you high-quality key insights needed to enhance your wearable devices and connected product portfolio but will also give you the opportunity to network with key players throughout the industry. We hope to welcome you to this must attend event in October 2023! \nBenefits of Attending: \n\nEngage with key regulatory updates surrounding digital health and medical devices\nDiscover advances in device design and development for large volume delivery via on-body injectors\nExplore the key drivers of novel drug products for the development for on-body injectors\nHear insights into the growing potential of digital health to improve patient experience and treatment\nDevelop your understanding of design strategies for connectivity and digital health\n\nDelegates will have the opportunity to network with the following companies: \n\nJohnson & Johnson\nBiogen\nAstraZeneca\nMerck KGaA\nNovartis\nNovo Nordisk\nBoehringer Ingelheim\n\nAnd many more!! \nWho Should Attend: \n\nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers of:\nDrug-Delivery Developers\nAutoinjectors\nDevice Engineering\nHuman Factors\nInjectables\nPackaging\nRegulatory Affairs\nConnectivity\nMedical Device Data\nNovel Product Technology\nSmart Device Developers\nDevice Safety Solution Providers\nor anyone who works with Wearable Devices/ On-Body Injectors within pharmaceuticals\, biotech\, device developers and solution providers.\n\nThe two-day conference will bring you high-quality insights and industry connections on the latest advances in wearable injectors and connectivity\, and a platform for exchanging ideas.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference-expo/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231010
DTEND;VALUE=DATE:20231013
DTSTAMP:20260515T223210
CREATED:20230628T105645Z
LAST-MODIFIED:20230628T105645Z
UID:37366-1696896000-1697155199@www.pharmajournalist.com
SUMMARY:6th Neuropsychiatric Drug Development Summit
DESCRIPTION:The Definitive Industry Forum for Spearheading Non-Psychedelic & Psychedelic R&D \n2023 is booming with novel psychiatric R&D and the promise of precision medicine for neuropsychiatric patients. Pipelines are gaining momentum\, with notable approvals on the horizon\, as unmet needs in PTSD\, bipolar\, anxiety\, schizophrenia\, depression\, and ADHD become greater and greater. There is\, therefore\, a huge deal of novel and promising research to be discussed this October at the 6th Neuropsychiatric Drug Development Summit. \nWith discovery\, preclinical\, translational\, and clinical scientists from the likes of Biogen\, Otsuka\, AbbVie\, Genentech\, Lundbeck\, Delix Therapeutics\, Atai\, Gilgamesh\, and Cerevel Therapeutics\, don’t miss the field’s favorite conference\, specifically dedicated to biopharma’s most pressing challenges of de-risking the translational gap and advancing transformative neuropsychiatric candidates through the clinic. \nTo know more visit: https://ter.li/sar413
URL:https://www.pharmajournalist.com/event/6th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231020
DTSTAMP:20260515T223210
CREATED:20230524T141827Z
LAST-MODIFIED:20230524T141827Z
UID:37236-1697414400-1697759999@www.pharmajournalist.com
SUMMARY:14th World ADC San Diego 2023
DESCRIPTION:The ADC renaissance shows no sign of slowing down with the ground-breaking approval of ELAHERE for platinum resistant ovarian cancer\, Pfizer’s jaw-dropping acquisition of Seagen for $43 billion\, and BMS’ $1 billion+ pact with Tubulis. There has been no better time to reunite the World ADC community and invest in progressing ADCs to front line treatments for patients. \nThe highly anticipated 14th World ADC San Diego (October 16-19\, 2023 | San Diego\, CA) returns as the world’s largest industry-dedicated discussion and networking forum addressing and overcoming the challenges in end-to-end ADC development. \nGain exclusive access to the full event guide to view the full agenda with 120+ industry-leading speakers. \nWhether you’re new to the field or an ADC guru\, there is something for everyone included in this year’s agenda. Some of your must-attend talks per track include: \n\nDiscovery Chemistry: Join Christopher Marvin\, Principal Research Scientist\, AbbVie as he reviews the design and optimization of glucocorticoid receptor modulator payloads for Immunology ADCs\nCellular Biology: Discuss with Robert Lawrence\, Principal Scientist\, Seagen the influence of artificial intelligence on ADC target discovery\nTranslational: Review a best-in-class translational study with Meijuan Li\, Vice President\, Head of Translational Sciences & Biostatistics\, Eisai Oncology\nClinical Lessons: Be the first to hear industry-changing clinical results from ImmunoGen\, Byondis\, Iksuda Therapeutics\, Seagen\, Bliss Bio\, Genentech and Elucidia Oncology\nProcess and Analytical Development: Debate the key considerations for ADC comparability studies in a dedicated roundtable lead by ADC CMC expert\, Julie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nManufacturing and Supply Chain: Explore the manufacturing of novel dolaLock ADCs with supply chain architecture with Engin Ayturk\, Executive Director\, CMC Process Development\, Mersana Therapeutics\n\nAccess to the complete agenda here including a 7-tracked seminar day and 10 industry-beating workshops. \nDon’t miss out on the chance to reunite with the antibody-drug conjugate community while reflecting on the exciting year that ADCs have had\, and building momentum for the future of this innovative field.
URL:https://www.pharmajournalist.com/event/14th-world-adc-san-diego-2023/
LOCATION:Sheraton San Diego Hotel and Marina\, 1380 Harbor Island Dr\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260515T223210
CREATED:20230718T090856Z
LAST-MODIFIED:20230718T090856Z
UID:37484-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:2nd Operationalise: Early Access Programmes Europe Summit
DESCRIPTION:The Early Access Programmes Summit Europe returns for a second year this October\, aiming to help the industry navigate the notoriously complex European regulatory landscape\, and conquer operational hurdles to provide patients in Europe with early access to medicines. \n \nThis meeting provides a forum to address burning questions and share ideas on topics such as European regulatory guidelines\, labelling\, supply\, and best practices around reimbursement\, integrating of pre- and post-trial access programmes and scoping. \nProviding practical\, valuable case studies is this year’s expert speaker lineup including the likes of GlaxoSmithKline\, Roche\, Novartis\, Sanofi\, and many others! Visit our website to download a free copy of the full event guide to explore the jam-packed 3-day agenda and full speaker faculty. \nWhether you’re a veteran at managing early access programmes and are looking to expand your geo\, or a new entrant to the field\, you’ll leave this conference with the practical lessons and essential connections needed to supercharge your European early access programme across 2023 and beyond. \nTo know more visit: https://bit.ly/3K4BpqO
URL:https://www.pharmajournalist.com/event/2nd-operationalise-early-access-programmes-europe-summit/
LOCATION:Hilton Canary Wharf\, South Quay\, Marsh Wall\, London\, E14 9SH\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231016
DTEND;VALUE=DATE:20231019
DTSTAMP:20260515T223210
CREATED:20230831T083951Z
LAST-MODIFIED:20230905T090233Z
UID:37702-1697414400-1697673599@www.pharmajournalist.com
SUMMARY:4th Commercializing Flow Chemistry Summit
DESCRIPTION:Scaling Flow Chemistry for Sustainability\, Safety and Speed to Market  \nWith the growing demand for better flow technology\, the 4th Commercializing Flow Chemistry Summit is your must-attend meeting to deep-dive into transforming your process efficiency\, emerging technology toolbox and economic gains through strategic flow chemistry. \nWith unmissable case studies from the likes of Novartis\, Boehringer Ingelheim\, Sanofi\, AbbVie\, Eli Lilly and Takeda\, this is the definitive forum to benchmark and learn with this forward-thinking community who reunite once more. \nThese industry titans have collaborated to form a comprehensive\, 3-day program covering key topics including: \n\nElevate Sustainability with Industry Leaders: Join forces with Merck\, Eli Lilly and AbbVie to integrate sustainable practices seamlessly into your workflow\, enhancing both environmental responsibility and operational excellence\nUnlock Efficiency through Automation: Discover the power of automation in flow chemistry\, following the footsteps of efficiency leaders like Sanofi\, Takeda\, and Boehringer Ingelheim\, and optimize your processes for peak performance\nMaster Multi-Step Techniques: Gain expert insights from Boehringer Ingelheim on handling multi-step reactions in both flow and batch setups\, fine-tuning your manufacturing processes for maximum efficiency and output\n\nDon’t miss this opportunity to streamline your continuous chemistry research into scaled commercial applications\, and together with 80+ process chemists\, engineers\, and modellers\, go beyond reaction to work up optimization to develop winning processes quicker and expedite your drug development. \nTo know more visit: https://ter.li/jfxs1m
URL:https://www.pharmajournalist.com/event/4th-commercializing-flow-chemistry-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231017
DTEND;VALUE=DATE:20231020
DTSTAMP:20260515T223210
CREATED:20230724T153358Z
LAST-MODIFIED:20230724T153358Z
UID:37509-1697500800-1697759999@www.pharmajournalist.com
SUMMARY:2nd Innate Killer Summit Europe 2023
DESCRIPTION:The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T\, NK\, iNKT\, neutrophil\, and macrophage developers in October to chase the holy grail of efficacious\, off-the-shelf\, solid tumour immunotherapies through effective and scalable engineering\, engager and combination strategies that promote safe\, potent and persistent innate immune therapies following application. \nDon’t miss this chance to network with innate immune trailblazers from the likes of Sanofi\, Takeda\, Lift Biosciences\, Mink Therapeutics\, Affimed\, Carisma Therapeutics\, Arovella Therapeutics and receive 3-days of some of the best scientific and data driven case studies that will help propel your innate immune therapy into the clinic and beyond. Learn more – https://ter.li/nkcwg3
URL:https://www.pharmajournalist.com/event/2nd-innate-killer-summit-europe-2023/
LOCATION:Crowne Plaza London\, Royal Victoria Dock\, Western Gateway\, London\, E16 1AL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231026
DTSTAMP:20260515T223210
CREATED:20230628T104642Z
LAST-MODIFIED:20230628T104642Z
UID:37361-1698019200-1698278399@www.pharmajournalist.com
SUMMARY:11th IMPACCT: Real World Evidence Summit 2023
DESCRIPTION:Returning for its 11th year\, the IMPACCT: Real World Evidence Summit 2023 will deep dive into the use of RWE for regulatory submissions and clinical trial innovation to unlock unstructured healthcare data and transform disease treatment. \nJoin 100+ senior leaders in RWE\, RWD\, real world analytics & epidemiologists from pharma and biotech to take part in this three-day summit with over 18 hours of exclusive content. \nDon’t miss your unique opportunity to explore how to leverage RWE to target patient populations and drive DE&I into trials. For more information go to: https://ter.li/db1xte
URL:https://www.pharmajournalist.com/event/11th-impacct-real-world-evidence-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231023
DTEND;VALUE=DATE:20231025
DTSTAMP:20260515T223210
CREATED:20230810T114239Z
LAST-MODIFIED:20230810T114239Z
UID:37598-1698019200-1698191999@www.pharmajournalist.com
SUMMARY:Biosensors for Medical Wearables Conference and Expo
DESCRIPTION:Biosensors for Medical Wearables Conference and Expo  \n*In collaboration with Medical Design Briefs* \nOctober 23-24\, 2023 | Boston\, MA\, USA \nhttp://www.biosensors-medical-wear.com/PharmaJournalist-WL \nSAE Media Group’s 3rd Annual Biosensors for Medical Wearables Conference will be back for 2023 in Boston to bring together device developers\, MedTech\, component manufacturers and big pharma to share and discuss the exciting advances in the medical wearable technology landscape. \nThe wearable biosensors market has grown significantly in recent years leading to increasingly growing potential for medical applications and at home alternatives for patients. With growing applications and potential in remote patient monitoring\, diagnosis\, therapeutics and detection of disease\, wearable sensors are attracting considerable interest due to their opportunities in better supporting patients\, clinical outcomes and decisions. Furthermore\, AI and connected technologies are furthering the potential opportunities of this industry. However\, challenges including flexibility of wearable devices\, the collection of clinical-grade data and advanced battery technologies still remain for the industry to overcome. This year’s conference looks to address these hot topics through case studies and industry insights. \nThis is a must attend event\, giving you the chance to engage in the latest innovations that are accelerating the wearable biosensors industry. We hope to welcome you in October 2023! \nReasons to attend: \n\nBenchmark against and explore the latest biosensor technologies for wearable medical devices from Abbott\, Empatica and Hexoskin\nDelve into the potential of wearable sensors and digital tools in decentralized diagnosis including a Johnson & Johnson case study on the Heartline project\nLearn how game changing companies such as Philips and Medtronic are utilizing wearables to maximize remote patient monitoring opportunities for wider patient populations\nExplore how AI and machine learning technologies are enabling optimized data collection and streamlined data analysis\nDiscover cutting-edge biosensor therapeutic applications for neurology with Neurasantys and a panel discussion on future medical opportunities\n\nWho you can meet? \n\nAndreas Caduff\, Strategic Advisory Board\, DiME\nLorelie Villarete\, Manager\, Clinical Affairs\, Lingo Sensing Technology Unlimited Company (an Abbott Company)\nTim Callahan\, VP Scientific Affairs\, Philips\nKara Chappie\, Director and Project Lead\, Pfizer\nJason Case\, Vice President\, Research and Development\, Patient Monitoring\, Medtronic\nJames Mault\, MD\, Founder and CEO\, BioIntellisense\, Inc.\nJasmin Imsirovic\, Associate Director\, Takeda\nJanet Nikolovski\, New Venture Lead – Genitourinary Oncology\, Johnson & Johnson
URL:https://www.pharmajournalist.com/event/biosensors-for-medical-wearables-conference-and-expo/
LOCATION:COURTYARD BY MARRIOTT BOSTON DOWNTOWN\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="SAE MEDIA GROUP":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231030
DTEND;VALUE=DATE:20231102
DTSTAMP:20260515T223210
CREATED:20230803T103923Z
LAST-MODIFIED:20230803T103923Z
UID:37564-1698624000-1698883199@www.pharmajournalist.com
SUMMARY:CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:CRISPR-based therapies are undergoing a remarkable evolution\, with drug developers striving to enhance the safety\, precision and efficacy of their products. As this paradigm takes place\, more complex CRISPR structures necessitate cutting-edge advancements in analytical methods and tools to effectively characterize the genome-edited products utilizing CRISPR technology. \nAs industry experts tread unchartered territory\, the inaugural CRISPR-Based Therapy Analytical Development Summit has been convened\, gathering more than 60 distinguished experts in analytical development devoted to the creation\, refinements and implementation of more robust analytical tools specifically tailored to CRISPR-based constructs. \nWithin this intimate space\, we will adopt a shared consensus and delve into a comprehensive array of analytical techniques central to any CRISPR-based toolkit. Topics of discussion will span pioneering technology that includes everything from novel methods to characterize the guide RNA and whole CRISPR complex\, to the use of next-generation sequencing (NGS) to detect and assess off-targets for superior safety evaluations. \nIn response to the regulatory bodies’ insistence on high-quality data to substantiate the safety and efficacy of genome-edited products\, this summit is imperative to all individual engaged in the development of analytical tools and methodologies utilizing CRISPR technology as we build for better guidance around CRISPR-edited products. \nIf your role centers around analytical expertise and gene edited specialization\, this meeting will enable you to streamline your analytical development process and connect in a shared goal to deliver safer therapies\, with superior therapeutic benefit to patients faster. \nTo know more visit: https://ter.li/28jg6x
URL:https://www.pharmajournalist.com/event/crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231106
DTEND;VALUE=DATE:20231110
DTSTAMP:20260515T223210
CREATED:20230628T105940Z
LAST-MODIFIED:20230628T105940Z
UID:37371-1699228800-1699574399@www.pharmajournalist.com
SUMMARY:5th Gene Therapy for Neurological Disorders Summit
DESCRIPTION:Accelerating More Transformative Gene Therapies for CNS Disorders \nDespite a challenging 2022 for Gene Therapy developers targeting the CNS\, the recent approvals of Skysona by bluebird bio and Upstaza by PTC Therapeutics have validated the potential that gene therapies can act as transformative medicines within the CNS community. \nThe 5th Gene Therapy for Neurological Disorders Summit is your comprehensive 4-day event to stay ahead of cutting-edge developments\, overcome delivery challenges\, address translational bottlenecks\, and create a bulletproof clinical development strategy\, to propel the next wave of CNS gene therapies forward. \nThis summit will unite 200+ gene therapy and neurology leaders with a program designed to cater to everyone from Discovery through to Clinical Development; this is your only opportunity for a cover-to-cover discussion full of need-to-know and practical insights. \nNow that the neurological gene therapy field has been given a renewed sense of direction\, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders. \nTo know more visit: https://ter.li/iblyl1
URL:https://www.pharmajournalist.com/event/5th-gene-therapy-for-neurological-disorders-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR